TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor Innovations in Oncology Event

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the following event at 1:00 p.m. ET on Wednesday, Sept. 28, 2022: Virtual Investor Innovations in Oncology – Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (“GBM”). As part of the virtual event, Climaco will discuss the company’s ongoing potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. Interested parties should visit https://ibn.fm/ktCnW to register for the webinar. A live video webcast of the event will be available on the company’s website, and a webcast replay will be available two hours following the live presentation and accessible for 90 days.

To view the full press release, visit https://ibn.fm/roGhO

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork

Christian Amiscua

Share
Published by
Christian Amiscua

Recent Posts

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Secures Roles in Two U.S. Army Microgrid Projects Valued at $144.6 Million

AZIO AI Holdings (NASDAQ: AZIO), a developer of power infrastructure for artificial intelligence ("AI") campuses,…

2 days ago

TinyGemsBreaks – ZenaTech, Inc. (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) Surpasses C$20 Million in Contracted Revenue Backlog Across Global Operations

ZenaTech (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) announced that its consolidated contracted revenue backlog has…

3 days ago

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Signs Agreement to Support $144.6 Million in U.S. Army Microgrid Contracts

AZIO AI Holdings (NASDAQ: AZIO) announced it has signed a general contracting agreement with Energy…

3 days ago

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Establishes Space and Government Power Team to Pursue Lunar and Defense Infrastructure Opportunities

AZIO AI Holdings (NASDAQ: AZIO) announced the formation of a dedicated space and government power…

4 days ago

TinyGemsBreaks – ZenaTech, Inc. (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) Secures Energy Sector Survey Contracts With Potential Follow-On Work Totaling Nearly C$1 Million

ZenaTech (NASDAQ: ZENA)  (FSE: 49Q) (BMV: ZENA) announced that its Drone as a Service ("DaaS")…

5 days ago